0.00Open0.00Pre Close0 Volume0 Open Interest6.00Strike Price0.00Turnover0.00%IV-282.17%PremiumDec 20, 2024Expiry Date4.43Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Gain Therapeutics Stock Discussion
$Gain Therapeutics (GANX.US)$
$Edible Garden (EDBL.US)$
All Short
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
📊⚡️📊
📊⚡️📊
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure
shared via @Teddy123 Thanks!!
No comment yet